Iambic Therapeutics Inc
03/02/2026 | Press release | Archived content
Iambic to Participate in March Investor Conferences
SAN DIEGO, CA - March 2, 2026 -- Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven drug discovery platform, today announced its participation in upcoming March investor conferences:
- Leerink Partners Global Healthcare Conference: March 9-12
- Jefferies Biotech Summit: March 10-11
- KeyBanc Healthcare Forum: March 18-19
About Iambic
Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, internally and with partners, to address urgent unmet patient need as well as providing access to its industry-leading technology. Learn more about the Iambic team, platform, pipeline, and partnerships at Iambic.ai
Iambic Therapeutics Inc published this content on March 02, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 28, 2026 at 07:03 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]